PubMed Health⌕ Search

Biomedical subjects

K W Gee

Publications and source records attributed to K W Gee.

At least 37 records · Page 2Linked to original sources
PubMed1995

Selective actions of certain neuroactive pregnanediols at the gamma-aminobutyric acid type A receptor complex in rat brain.

Certain endogenous pregnanediols (5 alpha-pregnan-3 alpha,20 alpha-diol and 5 beta-pregnan-3 alpha,20 beta-diol) were observed to have limited efficacy as allosteric modulators of t-[35S]butylbicyclophosphorothionate ([35S]TBPS) and [3H]flunitrazepam binding to sites on the gamma-aminobutyric acid (GABA)A receptor complex in rat brain. In contrast, 3 alpha-hydroxy-5 alpha-pregnan-20-one (3 alpha,5 alpha-P) and 3 alpha-hydroxy-5 beta-pregnan-20-one (3 alpha,5 beta-P) have full efficacy. Moreover, 3 alpha,5 beta-P but not 3 alpha,5 alpha-P recognizes high (nanomolar) and low (micromolar) affinity neuroactive steroid sites in these allosteric modulatory assays. The concentration-response curve for 3 alpha,5 alpha-P modulation of [35S]TBPS binding was shifted rightward in the presence of these pregnanediols and GABA. The maximum shift produced by these pregnanediols never exceeded the concentration-response curve obtained with 3 alpha,5 alpha-P alone in the absence of GABA. Additionally, neither 5 alpha-pregnan-3 alpha,20 alpha-diol nor 5 beta-pregnan-3 alpha,20 beta-diol had any effect on the site recognized by 3 alpha,5 alpha-P in the absence of GABA. The difference in the affinities of the two apparent sites (29 nM versus 152 nM in the presence and absence of GABA, respectively) recognized by 3 alpha,5 alpha-P is only approximately 5-fold. In contrast, the difference between the high (30 nM) and low (7 microM) affinity sites discriminated by 3 alpha,5 beta-P is > 200-fold. Thus, the selective interaction between the high affinity site recognized by 3 alpha,5 beta-P and these pregnanediols can be clearly observed. A saturating concentration of 5 beta-pregnan-3 alpha,20 beta-diol selectively eliminated the high affinity component recognized by 3 alpha,5 beta-P, whereas 5 alpha-pregnan-3 alpha,20 alpha-diol did not completely abolish the high affinity site. 5 alpha-Pregnan-3 alpha,20 alpha-diol recognized only a portion of the high affinity sites discriminated by 3 alpha,5 beta-P, relative to 5 beta-pregnan-3 alpha,20 beta-diol, whereas the two pregnanediols recognized a similar population of sites mediating 3 alpha,5 alpha-P inhibition of [35S]TBPS binding. Collectively, these studies provide evidence that the limited efficacy of certain pregnanediols as allosteric modulators of [35S]TBPS binding may be explained in part by selectivity for the high affinity site recognized by 3 alpha,5 beta-P.(ABSTRACT TRUNCATED AT 400 WORDS)

Animals↗
PubMed1995

Influence of the estrus cycle on the discrimination of apparent neuroactive steroid site subtypes on the gamma-aminobutyric acidA receptor complex in the rat.

Estrus cycle-related changes in gamma-aminobutyric acid (GABA)A receptor complex (GRC) sensitivity to modulation by reduced progesterone metabolites is suggestive of a possible mechanism for maintaining brain homeostasis in the presence of fluctuating levels of these neuroactive metabolites. In addition, certain endogenously occurring pregnanediols are selective for apparent neuroactive steroid site subtypes discriminated by the progesterone metabolite 3 alpha-hydroxy-5 beta-pregnan-20-one (3 alpha,5 beta-P) on the GRC. Thus, it was of interest to evaluate the influence of gender and the estrus cycle on the ability of 3 alpha,5 beta-P and its 20-reduced analog 5 beta-pregnan-3 alpha,20 beta-diol to differentiate neuroactive steroid site subtypes. Neuroactive steroid modulation of [35S]t-butylbicyclophosphorothionate ([35S]TBPS) binding to the GRC in rats during estrus, diestrus and after ovariectomy (OVX) was measured in washed cortical P2 homogenates in the presence or absence of exogenous GABA. During diestrus, the inability of 5 beta-pregnan-3 alpha,20 beta-diol to allosterically modulate [35S]TBPS binding in the absence of GABA coincides with the inability of 3 alpha,5 beta-P to modulate [35S]TBPS binding with high potency. In contrast, the addition of GABA to the assay produced high potency inhibition of [35S]TBPS binding by each steroid. Remarkably, although findings in diestrus and OVX homogenates were no different from those observed in males, the proportions and IC50 values of the two sites discriminated by 3 alpha,5 beta-P in [35S]TBPS binding assays during the estrus phase were significantly different from male, OVX and diestrus rats.(ABSTRACT TRUNCATED AT 250 WORDS)

Allosteric Regulation↗
PubMed1995

A putative receptor for neurosteroids on the GABAA receptor complex: the pharmacological properties and therapeutic potential of epalons.

A critical mass of evidence now supports the existence of a novel class of neuroactive steroids. These steroids are devoid of any known steroid hormone activity and have high specificity for the gamma-aminobutyric acidA receptor complex (GRC), which is a ligand-gated chloride channel that mediates the inhibitory action of the neurotransmitter gamma-aminobutyric acid (GABA). The action of these steroids at the GRC is to allosterically potentiate the effect of GABA on chloride channel conductance through a unique site on the GRC. These neuroactive steroids have been termed the epalons, a shortened form of epiallopregnanolone, an endogenous metabolite of progesterone with potent actions at the GRC. Putative epalon receptors may be unique sites on the GRC that mediate the effects of epalons on GABA-gated channel function. The pharmacological profile of the epalons is consistent with those of other positive modulators of GABA action (e.g., the clinically useful benzodiazepines (BZs) and barbiturates). These neuroactive steroids have anxiolytic, anticonvulsant, and sedative-hypnotic properties. Based upon some of the unique characteristics of the epalons relative to barbiturates and the BZs, it is plausible that the epalons can be developed into a novel class of therapeutic agents for the treatment of anxiety, epilepsy, and insomnia.

Brain↗
PubMed1994

The neuroactive steroid 3 alpha-hydroxy-5 beta-pregnan-20-one is a two-component modulator of ligand binding to the GABAA receptor.

Neuroactive steroids allosterically inhibit [35S]t-butylbicyclophosphorothionate ([35S]TBPS) and enhance [3H]flunitrazepam binding to the GABAA receptor complex. In the presence of 5 microM GABA, 3 alpha-hydroxy-5 beta-pregnan-20-one (3 alpha, 5 beta-P) inhibits [35S]TBPS binding with high- (IC50 21-32 nM) and low- (IC50 24-63 microM) affinity components in bovine cortical, cerebellar, and hippocampal membranes. The percentage of high-affinity sites ranges from 53% in cortex to 65% in cerebellum and hippocampus. However, 3 alpha, 5 beta-P is a single-site inhibitor in thalamus (IC50 43 nM). In the absence of GABA, similar affinities for the high- and low-affinity components were detected, although the percentages of high-affinity sites were reduced. Similarly, 3 alpha, 5 beta-P enhances [3H]flunitrazepam binding with high- (EC50 44-58 nM) and low- (EC50 2-13 microM) affinity components which account for 71-77% and 23-29% of the sites, respectively, in cortex, cerebellum and hippocampus. 3 alpha, 5 beta-P is a single-site enhancer in thalamus (EC50 80 nM). In contrast to 3 alpha,5 beta-P, 3 alpha-hydroxy-5 alpha-pregnan-20-one (3 alpha,5 alpha-P) is a single site modulator of [35S]TBPS and [3H]flunitrazepam binding in all regions examined. These data provide pharmacological evidence consistent with receptor heterogeneity for neuroactive steroids.

20-alpha-Dihydroprogesterone↗
PubMed1994

Neuroactive steroid actions at the GABAA receptor.

Neuroactive steroids are a new class of steroids that do not interact with any of the classical cytosolic hormonal steroid receptors. The most well-documented examples are those that interact with the gamma-aminobutyric acidA (GABAA) receptor/chloride channel complex in the central nervous system. The GABAA receptors are known to contain allosteric modulatory sites for therapeutically useful drugs such as benzodiazepines (BZs) and barbiturates. The interaction of neuroactive steroids with the GABAA receptor is specific to a site on the receptor complex distinct from the benzodiazepine and barbiturate modulatory sites. Neuroactive steroids exist endogenously; the examples are metabolites of progesterone and deoxycorticosterone, 3 alpha-hydroxy-5 alpha-pregnane-20-one, and 5 alpha-pregnane-3 alpha, 21 alpha-dihydroxy-20-one, respectively, and their 5 beta stereoisomers. The GABAA receptor agonist-like effects that these neuroactive steroids produce in vivo are similar, but not identical, to those of BZs and barbiturates. Representatives of all three classes of modulators are active as sedative-hypnotics, anticonvulsants, and anxiolytics in animal models. Because of the heterogeneity of GABAA receptors and their differential distribution in the brain, dissimilar in vivo pharmacological profiles displayed by BZs, barbiturates and neuroactive steroids are not surprising. Studies of neuroactive steroid interactions with the GABAA receptor revealed a unique subset of these steroids that modulate the receptor with limited efficacy. Another endogenously occurring progesterone metabolite, 5 alpha-pregnane-3 alpha,20 alpha-diol, is an example of this subset of neuroactive steroids. At present, it is not clear whether the observed limited efficacy is due to receptor subtype selectivity, partial agonist activity or both.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗
PubMed1994

The estrus cycle, sensitivity to convulsants and the anticonvulsant effect of a neuroactive steroid.

Recent in vitro work in our laboratory suggests that functional sensitivity of the gamma-aminobutyric acidA receptor complex to the neuroactive progesterone metabolite 3 alpha-hydroxy-5 alpha-pregnan-20-one (3 alpha,5 alpha-P) changes during the estrus cycle. Therefore, the current in vivo studies were conducted to evaluate estrus cycle-related differences in sensitivity to convulsants and the anticonvulsant effect of 3 alpha, 5 alpha-P. The threshold dose for onset to myoclonic twitch, running bouncing clonus and tonic hind-limb extension was measured by constant i.v. infusion of (+)-bicuculline, picrotoxin, pentylenetetrazol, strychnine and methyl-6,7-dimethoxy-4-ethyl-beta- carboline-3-carboxylate. Females in estrus were more sensitive than females in diestrus 1 or males to (+)-bicuculline and methyl-6,7-dimethoxy-4-ethyl-beta-carboline-3- carboxylate. Administration of 3 alpha, 5 alpha-P (15 mg/kg i.p. in beta-cyclodextrin) 15 min before infusion of pentylenetetrazol significantly increased the threshold dose for onset to all three convulsions and provided equal protection against tonic convulsions. The dose for onset to myoclonic twitch was significantly higher in females in diestrus 1 than females in estrus or males. Plasma 3 alpha, 5 alpha-P did not differ between groups injected with 3 alpha, 5 alpha-P, suggesting that the difference in sensitivity to the anticonvulsant effect of 3 alpha, 5 alpha-P was not pharmacokinetic.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗
PubMed1993

A comparison of Ro 16-6028 with benzodiazepine receptor 'full agonists' on GABAA receptor function.

Ro 16-6028 (bretazenil) has a pharmacological profile characteristic of a partial agonist at the gamma-aminobutyric acidA (GABAA) receptor-linked benzodiazepine site. The present study utilized modulation of [35S]t-butylbicyclophosphorothionate ([35S]TBPS) binding and enhancement of GABA-stimulated 36Cl- uptake to further assess Ro 16-6028's partial agonist profile in vitro. Ro 16-6028 was the most potent benzodiazepine examined, exhibiting an IC50 (concentration at which half-maximal inhibition of specific [35S]TBPS binding occurs) of 6.1 nM, compared to clonazepam (7.9 nM), flunitrazepam (13.6 nM) and diazepam (91.1 nM). The rank order of potency for inhibition of [35S]TBPS binding was identical to that for inhibition of [3H]flunitrazepam binding. However, Ro 16-6028 was less efficacious in that it produced 27% inhibition of specific [35S]TBPS binding, compared to clonazepam (34%), flunitrazepam (41%) or diazepam (49%). Ro 16-6028 antagonized the inhibition of [35S]TBPS binding produced by 10 microM diazepam. Ro 16-6028 was also more potent and less efficacious than diazepam in potentiating GABA-stimulated 36Cl- uptake. These results provide further evidence that Ro 16-6028 is acting as a partial agonist at the benzodiazepine receptor in modulating function of the GABAA receptor complex.

Animals↗
PubMed1993

The influence of estrus cycle on neurosteroid potency at the gamma-aminobutyric acidA receptor complex.

The reduced metabolites of progesterone (3 alpha-hydroxy-5 alpha-pregnan-20-one or 3 alpha,5 alpha-P) and deoxycorticosterone (3 alpha,21-dihydroxy-5 alpha-pregnan-20-one or 5 alpha-THDOC) exhibit a gamma-aminobutyric acid (GABA) agonist pharmacological profile and bind with high affinity to a unique steroid recognition site on the GABAA receptor complex (GRC). In female rats, peak levels of 3 alpha,5 alpha-P occur between proestrus and estrus and at concentrations which appear sufficient to affect GRC-mediated inhibitory events. Therefore, steroid modulation of the binding of [35S]t-butylbicyclophosphorothionate was conducted to examine sensitivity of the GRC during the estrus cycle. The results in unwashed tissue (cortex, cerebellum, hippocampus and striatum) indicated that 3 alpha, 5 alpha-P was most potent in estrus. Subsequent studies in washed tissue and in washed tissue plus 3 microM (+)bicuculline indicated that 3 alpha,5 alpha-P was more potent in diestrus 1 than in estrus. Brain regional differences in potency of 3 alpha,5 alpha-P were also observed. Overall, the results in washed tissue suggest that an inherent change in the sensitivity of the GRC occurs during the estrus cycle, whereas the results in unwashed tissue may be influenced by the presence of endogenous GRC-active neurosteroids and GABA. The change in sensitivity of the GRC during the estrus cycle may occur to help maintain homeostatic regulation of brain excitability.

Animals↗
PubMed1992

Complex interactions between the steroid derivative RU 5135 and the GABAA-receptor complex.

The modulation of [35S]t-butylbicyclophosporothionate ([35S]TBPS) binding was used to evaluate the actions of the steroid derivative RU 5135 at the gamma-aminobutyric acidA (GABAA) receptor complex. The inhibition of [35S]TBPS binding by GABA in the presence of various concentrations of RU 5135 was consistent with the hypothesis that RU 5135 is a competitive antagonist at the GABAA receptor. Despite common structural features (i.e., 3 alpha-hydroxylated, 5 beta-reduced A ring) with GABAA receptor-active neurosteroids, RU 5135 did not appear to be competitive at the putative steroid site on the GABAA receptor-active, as demonstrated by Schild analysis of 5 alpha-pregnane-3 alpha-ol-20-one (3 alpha,5 alpha-P) modulation of [35S]TBPS binding in the presence of different concentrations of RU 5135. On the other hand, the reduced potency of 3 alpha,5 alpha-P as an inhibitor of [35S]TBPS binding in the presence of RU 5135, as well as blockade of 5 alpha-pregnane-3 alpha-20 alpha-diol (5 alpha-pregnanediol) inhibition of [35S]TBPS binding by RU 5135 provide further support for the GABAA receptor antagonist properties of RU 5135. Moreover, this amidine steroid was able to partially inhibit [35S]TBPS binding independent of GABA with nanomolar potency; yet the mechanism by which this occurs remains to be determined.

Androstanes↗
PubMed1991

Anxiolytic activity of the progesterone metabolite 5 alpha-pregnan-3 alpha-o1-20-one.

3 alpha-hydroxylated pregnane steroids have been shown to possess anesthetic, hypnotic, anticonvulsant and anxiolytic properties. In this study, metabolites of progesterone and deoxycorticosterone, 5 alpha-pregnan-3 alpha-o1-20-one (3 alpha-OH-DHP) and 5 alpha-pregnan-3 alpha,21-diol-20-one (5 alpha-THDOC), respectively, were tested for anxiolytic effects in N.I.H. Swiss-Webster mice using the light/dark transition, open-field and lick-suppression tests. Similar to the benzodiazepine (BZ) diazepam, 3 alpha-OH-DHP (5-40 mg/kg) and 5 alpha-THDOC (5-40 mg/kg) significantly increased the number of light/dark transitions. 3 alpha-OH-DHP's effects were stereospecific as its diasteriomer, 3 beta-OH-DHP was devoid of activity. The benzodiazepine antagonist CGS-8216 (10 mg/kg) blocked diazepam's (1.0 mg/kg) anxiolytic effects, but did not have any effect against 3 alpha-OH-DHP (20 mg/kg). The data indicate that the pregnane steroids produce their anxiolytic effects through a separate mechanism than the BZs. 3 alpha-OH-DHP (20 mg/kg), 5 alpha-THDOC (20 mg/kg) and diazepam (1.0 mg/kg) increased activity in a open-field test. 3 beta-OH-DHP had no effect in the open-field test. Furthermore, 3 alpha-OH-DHP produced a 235% increase in punished responding in a lick-suppression test. These results demonstrate that the endogenous pregnane steroids possess anxiolytic effects that may be clinically relevant.

Animals↗
PubMed1991

Differential responses of expressed recombinant human gamma-aminobutyric acidA receptors to neurosteroids.

Neuroactive steroids, in particular 3 alpha-hydroxypregnanes, are allosteric modulators of the gamma-aminobutyric acidA (GABAA) receptor. Regionally selective expression of receptor subunit subtypes may account for differential responsiveness of tissues to GABAergic inhibition and neurosteroid modulatory effects. The effect of 5 alpha-pregnan-3 alpha-ol-20-one (epiallopregnanolone) on heterotropic cooperativity on the GABAA receptor complex has been studied in three subtypes of expressed recombinant human receptors and in rat brain and spinal cord. Steroid potentiation of [3H]flunitrazepam binding was greatest for the alpha 3 beta 1 gamma 2 receptor complex, whereas alpha 1 beta 1 gamma 2 and alpha 2 beta 1 gamma 2 complexes showed less than 100% enhancement in binding. Previous studies suggest that the spinal cord is devoid of alpha 1, whereas cerebellum is rich in alpha 1 subunits. Correspondingly, a differential enhancement of [3H]flunitrazepam binding in spinal cord (51%) versus cerebellum (28%) was also observed. The structure of neuroactive steroids is important in determinikng the extent of neuromodulatory activity. The 5 beta-pregnanes,5 beta-pregnan-3 alpha-ol-20-one (epipregnanolone) and 5 beta-pregnan-3 alpha,21-diol-20-one (5 beta-tetrahydrodeoxycorticosterone), were both less potent than their corresponding 5 alpha derivatives. A 3 alpha hydroxyl group is essential for neuromodulatory activity in the expressed receptors, as demonstrated by the observation that 5 alpha-pregnan-3 beta-ol-20-one (allopregnanolone) and 4-pregnen-3, 20-dione (progesterone) were both inactive.(ABSTRACT TRUNCATED AT 250 WORDS)

Allosteric Regulation↗
PubMed1991

Gamma-aminobutyric acidA receptor complexes in rat frontal cortex and spinal cord show differential responses to steroid modulation.

Regional differences in neuroactive steroid modulation of the gamma-aminobutyric acidA receptor-chloride ionophore complex (GBRC), as measured by t-butylbicyclophosphoro[35S]thionate ([35S] TBPS) binding and 36Cl- uptake, were demonstrated in rat spinal cord versus frontal cortex. The rank order of potencies of a series of 5 alpha- and 5 beta-reduced isomers of 3 alpha-hydroxylated steroids against [35S]TBPS binding were different between regions. The differences in rank order of potencies imply the possible existence of heterogeneous populations of GBRC-coupled steroid recognition sites. The relative potencies of selected 5 alpha- and 5 beta-reduced isomers as potentiators of 36Cl- uptake paralleled their potencies as inhibitors of [35S]TBPS binding. Differential sensitivity of the steroid recognition site to the allosteric influence of gamma-aminobutyric acid was also demonstrated. It appears that regionally specific responses to GBRC-active steroids do occur, although the functional consequences of these effects await evaluation in appropriate in vivo models.

Animals↗
PubMed1990

A steroid recognition site is functionally coupled to an expressed GABA(A)-benzodiazepine receptor.

Pregnane steroids, particularly 3 alpha-hydroxylated metabolites of progesterone, are known to have rapid and profound effects on brain excitability. Recent evidence suggests that the gamma-aminobutyric acid (GABA(A))-benzodiazepine receptor-Cl- ionophore complex may mediate these actions. The data further suggest that these steroids modulate the complex through a novel site independent of other known sites on the complex. The hypothesis that this site is on the GABA(A)-benzodiazepine receptor-Cl- ionophore complex is tested in the present study by determining its presence on transiently expressed GABAA-benzodiazepine receptors.

Cells, Cultured↗
PubMed1990

Steroids in relation to epilepsy and anaesthesia.

Increasing numbers of reports indicate direct effects of ovarian steroids on the central nervous system. Effects of progesterone and its metabolites on brain excitability in humans and in experimental animals have been studied. Anti-epileptic effects have been shown in cats and in women with partial epilepsy and well-defined epileptic foci. The reduced progesterone metabolite 5 alpha-pregnan-3 alpha-ol-20-one and its 5 beta analogue also decreased the epileptic activity resulting from a penicillin-induced cortical focus in cats. 5 alpha-Pregnan-3 alpha-ol-20-one protected mice against metrazol-, bicuculline- and picrotoxin-induced seizures but not against electroshock-and strychnine-induced seizures. Progesterone, 5 alpha-pregnan-3 alpha-ol-20-one and 5 beta-pregnan-3 alpha-ol-20-one also induce anaesthesia in humans and animals; in a rat model of anaesthesia 5 alpha-pregnan-3 alpha-ol-20-one was eight times more potent than methohexitone (the most potent anaesthetic barbiturate). Anaesthesia with loss of the eyelash reflex was observed in humans 75-90 seconds after the intravenous injection of 5 beta-pregnan-3 alpha-ol-20-one in lipid emulsion. The in vivo production and brain distribution of centrally active steroids has also been studied in relation to the phases of the ovarian and menstrual cycle. A subset of women with epilepsy show changes in seizure frequency in relation to hormonal variations during the menstrual cycle. In the luteal phase when progesterone levels are high the number of generalized seizures is low. It is possible that progesterone and its metabolites play a role in epileptic seizures and also in the premenstrual syndrome.

Anesthetics↗
PubMed1990

Anticonvulsant steroids and the GABA/benzodiazepine receptor-chloride ionophore complex.

The ability of steroids to influence brain excitability is well documented. Certain 3 alpha-hydroxylated pregnanes are known to possess anticonvulsant and sedative-hypnotic/anesthetic properties. It has been observed that the seizure susceptibility in menstruating women with catamenial epilepsy appears to be correlated with changes in ovarian steroid levels. However, the underlying mechanism of these steroid influences on brain activity has only been recently revealed by pharmacological studies. These studies have provided compelling evidence for the presence of a novel steroid recognition site on the GABAA-benzodiazepine receptor complex (GBRC). Steroids may interact with this site with high affinity and stereospecificity to enhance chloride channel conductance in a manner similar to that produced by benzodiazepines (BZs) or barbiturates. The existence of such a steroid site on the GBRC is further supported by recent experiments involving the transfection of GABAA receptor cDNAs into a human embryonic kidney cell line. Based on the knowledge of the structure-activity requirements for the interaction of steroids with this novel recognition site, it is conceivable that the development of new anticonvulsant steroids with high therapeutic indices can be achieved.

Animals↗